BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10671194)

  • 1. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand.
    Gramaglia I; Cooper D; Miner KT; Kwon BS; Croft M
    Eur J Immunol; 2000 Feb; 30(2):392-402. PubMed ID: 10671194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.
    DeBenedette MA; Wen T; Bachmann MF; Ohashi PS; Barber BH; Stocking KL; Peschon JJ; Watts TH
    J Immunol; 1999 Nov; 163(9):4833-41. PubMed ID: 10528184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.
    Tan JT; Whitmire JK; Ahmed R; Pearson TC; Larsen CP
    J Immunol; 1999 Nov; 163(9):4859-68. PubMed ID: 10528187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
    Habib-Agahi M; Phan TT; Searle PF
    Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costimulation of CD28- T lymphocytes by 4-1BB ligand.
    DeBenedette MA; Shahinian A; Mak TW; Watts TH
    J Immunol; 1997 Jan; 158(2):551-9. PubMed ID: 8992967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.
    Gramaglia I; Weinberg AD; Lemon M; Croft M
    J Immunol; 1998 Dec; 161(12):6510-7. PubMed ID: 9862675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of 4-1BB in immune responses.
    Vinay DS; Kwon BS
    Semin Immunol; 1998 Dec; 10(6):481-9. PubMed ID: 9826581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responses.
    Tan JT; Ha J; Cho HR; Tucker-Burden C; Hendrix RC; Mittler RS; Pearson TC; Larsen CP
    Transplantation; 2000 Jul; 70(1):175-83. PubMed ID: 10919597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
    Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
    Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
    J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting.
    Houtenbos I; Westers TM; Dijkhuis A; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
    Clin Cancer Res; 2007 Jan; 13(1):307-15. PubMed ID: 17170077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of 4-1BB:4-1BB ligand in cancer immunotherapy.
    Cheuk AT; Mufti GJ; Guinn BA
    Cancer Gene Ther; 2004 Mar; 11(3):215-26. PubMed ID: 14671675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
    Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
    Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
    Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
    Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.
    Munks MW; Mourich DV; Mittler RS; Weinberg AD; Hill AB
    Immunology; 2004 Aug; 112(4):559-66. PubMed ID: 15270726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of experimental autoimmune myocarditis by blocking T cell activation through 4-1BB pathway.
    Haga T; Suzuki J; Kosuge H; Ogawa M; Saiki H; Haraguchi G; Maejima Y; Isobe M; Uede T
    J Mol Cell Cardiol; 2009 May; 46(5):719-27. PubMed ID: 19233196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-immunisation with DNA encoding RANK/RANKL or 4-1BBL costimulatory molecules does not enhance effector or memory CTL responses afforded by immunisation with a tumour antigen-encoding DNA vaccine.
    Herd KA; Wiethe C; Tindle RW
    Vaccine; 2007 Jul; 25(28):5209-19. PubMed ID: 17544551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.